Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 11/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.66 |
| ▸ | CCKAR | P32238 | 4/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL642143 | 0.92 | CCKBR (0.85) | CCKBRCCKAR | |
| SCHEMBL8681438 | 0.90 | CCKBR (0.82) | CCKBRKCNH2CCKARCYP3A4MAPT | |
| SCHEMBL9468540 | 0.90 | CCKBR (0.82) | CCKBRKCNH2CCKARCYP3A4MAPT | |
| SCHEMBL8611432 | 0.90 | CCKBR (0.82) | CCKBRKCNH2CCKARCYP3A4MAPT | |
| SCHEMBL643226 | 0.89 | CCKBR (0.81) | CCKBRCCKAR | |
| SCHEMBL643406 | 0.88 | CCKBR (0.79) | CCKBRCCKAR | |
| SCHEMBL643976 | 0.88 | CCKBR (0.80) | CCKBRCCKAR | |
| SCHEMBL7550802 | 0.88 | CCKBR (0.78) | CCKBRKCNH2MAPT | |
| SCHEMBL7550799 | 0.88 | CCKBR (0.78) | CCKBRKCNH2MAPT | |
| SCHEMBL643077 | 0.87 | CCKBR (0.78) | CCKBRCCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | claimed |
| EP-1727550-B1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LTD (GB) | 2009-07-29 | — | — | EP | claimed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | claimed |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALA CORPORATION (US) | 2007-06-21 | — | — | US | claimed |
| EP-1727550-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | claimed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| WO-2005089769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | claimed |
| US-8853204-B2 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the RSV fusion protein | ARROW THERAPEUTICS LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-8119630-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2012-02-21 | — | — | US | disclosed |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | ARROW THERAPEUTICS LIMITED (GB) | 2010-01-21 | — | — | US | disclosed |
| US-7582624-B2 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2009-09-01 | — | — | US | disclosed |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | NOVARTIS PHARMACEUTICALA CORPORATION (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1727550-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBITOR OF THE RSV FUSION PROTEIN | Arrow Therapeutics Limited (GB) | 2006-12-06 | — | — | EP | disclosed |
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | ARROW THERAPEUTICS LIMITED (GB) | 2006-02-23 | — | — | US | disclosed |
| WO-2005090319-A1 | PROCESS FOR PREPARING BENZODIAZEPINES | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
| WO-2005089769-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A BENZODIAZEPINE DERIVATIVE AND AN INHIBIT OR OF THE RSV FUSION PROTEIN | ARROW THERAPEUTICS LIMITED (GB) | 2005-09-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040923-A1 | Benzodiazepine derivatives and pharmaceutical compositions containing them | GABRA6, CNR1, SIGMAR1 | CCKBR 195/4885KCNH2 314/4885CCKAR 137/4885 |
| US-20070293482-A1 | Process for Preparing Benzodiazepines | CNR1, SIGMAR1, GABRA3 | CCKBR 246/4885KCNH2 375/4885CCKAR 114/4885 |
| US-20100015063-A1 | Benzodiazepine Derivatives and Pharmaceutical Compositions Containing Them | GABRA6, CNR1, SIGMAR1 | CCKBR 197/4885KCNH2 340/4885CCKAR 137/4885 |
| US-20070142403-A1 | Pharmaceutical composition comprising a benzodiazepine derivative and an inhibitor of the rsv fusion protein | GABRP, TSPO, GABRA1 | CCKBR 2243/4885KCNH2 3917/4885CCKAR 2354/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.